Anti-Müllerian hormone (AMH) is currently the most stable and accurate clinical marker for evaluating ovarian reserve in women. It is secreted by the granulosa cells of pre-antral and small antral follicles in the ovaries. AMH levels directly reflect the remaining pool of oocytes in the ovaries. This article explains the definition, clinical roles, reference ranges, and management strategies related to AMH.
The primary physiological function of AMH is to inhibit the premature recruitment of primordial follicles, thereby slowing the rate of depletion of the oocyte pool.Therefore, a higher AMH value (<7ng/mL; if it exceeds 7ng/mL, it may indicate polycystic ovary syndrome) usually indicates a more adequate ovarian reserve.
Four Major Clinical Applications of AMH
- Assessment of Ovarian Reserve
AMH is unaffected by the menstrual cycle, oral contraceptives, or pregnancy and can be measured at any point in the cycle. It is currently the most reliable biomarker of ovarian function.
- Guidance for Assisted Reproductive Technology (ART) Protocols
AMH ≤ 1.1 ng/mL indicates poor ovarian response, with likely fewer oocytes retrieved. Physicians adjust controlled ovarian stimulation dosages based on the specific AMH value.
- Aid in the Diagnosis of Polycystic Ovary Syndrome (PCOS)
AMH levels are often significantly elevated in women with PCOS, typically ≥ 7 ng/mL, serving as one of the important diagnostic reference indicators.
- Prediction of Menopause Timing and Identification of Premature Ovarian Insufficiency (POI)
AMH declines with age; the rate of decline can estimate the years remaining until menopause. When AMH ≤ 0.7 ng/mL, the probability of natural conception is extremely low.
Reference Ranges for AMH (Common Laboratory Standards)
– 20–30 years: 2.0–7.0 ng/mL
– 31–35 years: 1.5–6.0 ng/mL
– 36–40 years: 0.8–4.0 ng/mL
– >40 years: usually < 1.0 ng/mL (most below 0.8ng/
Actual results should be interpreted according to the reference interval provided by the testing laboratory.
Is a Decline in AMH Reversible?
Age-related AMH decline is irreversible: this is a physiological process of natural reduction in ovarian reserve; AMH decline caused by non-age factors may be reversible: such as temporary declines caused by diseases, medications, lifestyle factors, etc., which may partially recover after the inducing factors are removed; current medical technology cannot restore AMH levels that have declined due to age to the levels of youth, but interventions can improve ovarian function and increase fertility.
– Maintain regular sleep patterns and avoid staying up late
– Adopt a balanced diet rich in isoflavones and antioxidants
– Engage in moderate aerobic exercise and keep body weight within the normal range
– Quit smoking and limit alcohol consumption
Commonly used ovarian health supplements in clinical practice include isoflavones, folic acid, and vitamins. Juvenex Reco18 contains all of these active ingredients and can improve decreased AMH levels and protect egg quality. Multiple studies have shown that in women under 35 years of age with mildly to moderately low AMH, continuous use of Juvenex Reco18 for 3–6 months can significantly reduce the rate of AMH decline, and oocyte quality-related parameters improve in some individuals (individual variation exists).
Populations Recommended for AMH Testing
– Women aged 30 and above who plan to conceive
– Women with irregular menstruation or oligo-ovulation
– Women preparing for in vitro fertilization (IVF) or other assisted reproductive technologies
– Women diagnosed with or suspected of having PCOS
– Women with a history of ovarian surgery, chemotherapy, or radiotherapy
Conclution
AMH provides objective data on ovarian reserve. Regular AMH testing helps women plan childbearing timing rationally, select appropriate fertility treatments, or implement protective measures early. Combining a healthy lifestyle with evidence-based supplementation (such as the clinically validated product Juvenex Reco18) can optimize reproductive outcomes within the existing ovarian reserve.